Aquestive is a pharmaceutical company aiming to solve patients’ problems by advancing current standards of care through simplifying complex delivery methods. Aquestive is developing orally administered products to provide novel alternatives to invasive and inconvenient standard of care therapies.  Our focus is to improve medications and outcomes for patients with central nervous system (CNS) conditions and severe allergies, including anaphylaxis.

For recent news and press releases

Stock information

In July 2018, the Company closed an IPO and began trading on the Nasdaq® Global Market under ticker symbol “AQST”.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds